FIG. 1.
Mean (SD) single-dose (day 1) and steady-state (week 2 to 4) plasma concentration-time profiles of telbivudine in HBV-infected patients following oral administration of escalating doses at 25, 50, 100, 200, 400, and 800 mg.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.